Clinical Trial Update: RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial evaluating whether 125I radioactive seed marking affects pathological complete response rates and prognosis after neoadjuvant t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 125I radioactive seed marking

Snippet

Sponsor: Pengfei Qiu | Conditions: Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING